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Background: Matrix Gla protein (MGP) is an important inhibitor of calcification. The objective of the present study
of patients with type 2 diabetes and normal or slightly altered kidney function was to evaluate levels of inactive,
dephospho-uncarboxylated MGP(dp-ucMGP) and total uncarboxylated MGP(t-ucMGP) and assess their links with
biological and clinical parameters (including peripheral vascular calcification).
Methods: The DIACART study is a cross-sectional cohort study of 198 patients with type 2 diabetes and normal or
slightly altered kidney function. Matrix Gla protein levels were measured with an ELISA and all patients underwent
multislice spiral computed tomography scans to score below-knee arterial calcification.
Results: In the study population as a whole, the mean dp-ucMGP and t-ucMGP levels were 627 ± 451 pM and
4868 ± 1613 nM, respectively. Glomerular filtration rate, age and current vitamin K antagonist use were independently
associated with dp-ucMGP levels. When the study population was divided according to the median peripheral arterial
calcification score, patients with the higher score displayed significantly lower t-ucMGP and significantly higher dp-ucMGP
levels. Furthermore, plasma dp-ucMGP was positively associated with the peripheral arterial calcification score (independently
of age, gender, previous cardiovascular disease and t-ucMGP levels).
Conclusions: High dp-ucMGP levels were independently associated with below-knee arterial calcification score in patients
with type 2 diabetes and normal or slightly altered kidney function. The reversibility of the elevation of dp-ucMGP levels and
the latter’s relationship with clinical events merit further investigation.
Keywords: Matrix gla protein, Type 2 diabetes, Peripheral calcificationBackground
Peripheral arterial disease (PAD) is a major vascular
complication and the leading cause of amputation in
people with diabetes. In patients with PAD, the tibial ar-
tery calcification score is a useful tool for identifying pa-
tients at high risk of amputation, since the score has
greater predictive value than traditional risk factors [1].
Indeed, diabetes accelerates atherosclerosis and increases
the incidence of vascular calcification (VC) [2,3]. In
people with diabetes, VC is present in both coronary ar-
teries and arteries of the lower limbs. Furthermore, VC
is an independent predictor of cardiovascular and overall* Correspondence: ziad.massy@apr.aphp.fr
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unless otherwise stated.mortalities in patients with type 2 diabetes [4]. Various
epidemiologic studies have identified specific biomarkers
(including osteoprotegerin, osteocalcin and others) for
VC in this population [5,6].
One of the most interesting calcification inhibitors is
matrix Gla-protein (MGP), a vitamin K-dependent protein
that is expressed by smooth muscle cells, fibroblasts,
chondrocytes and endothelial cells in a variety of tissues
(including arterial vessel wall). There is evidence to sug-
gest that full activation of MGP requires posttranslational
carboxylation and phosphorylation (Figure 1) [7,8]. In
order to measure vitamin K status, assays were developed
to measure the conformations of MGP with the least ac-
tivity, i.e. forms with no posttranslational modifications
(dephospho-uncarboxylated MGP (dp-ucMGP)) or at least
no gammaglutamyl carboxylation (total uncarboxylated
MGP (t-ucMGP)) [9]. In fact, dp-ucMGP does not possessLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain









Posttranslational modifications in MGP
Figure 1 The different forms of the matrix Gla protein (MGP).
legend: MGP needs two posttranslational modifications for maturation:
glutamate carboxylation and serine phosphorylation. Both modifications
are only partially accomplished. Besides the non-modified form (dp-ucMGP)
also partially modified species (dp-cMGP and p-ucMGP) and the fully
maturated form p-cMGP are present in the circulation. In this paper we
have tested dp-ucMGP and total ucMGP (t-ucMGP) (which consists of
the sum of dp-ucMGP and p-ucMGP). Since the plasma concentration
of p-ucMGP is about 10 thousand fold higher than that of dp-ucMGP,
the t-ucMGP assay virtually measures p-ucMGP.
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wall. Hence, the dp-ucMGP assay is a direct marker of
vascular vitamin K status. In both healthy subjects and pa-
tients, poor vascular vitamin K status (corresponding to
high circulating dp-ucMGP levels) is regarded as a risk
marker for forthcoming arterial calcification. Indeed, dp-
ucMGP was found to be associated with the severity of
aortic calcification in patients with chronic kidney disease
(CKD) [10]. Circulating t-ucMGP levels are at least 1000-
fold higher than those of dp-ucMGP, and are thought to
consist mainly of phosphorylated uncarboxylated MGP
(p-ucMGP) species, i.e. MGP-related antigens with be-
tween 1 and 3 high-affinity calcium-binding groups. This
explains why immunohistochemical techniques invariably
find ucMGP to be closely associated with calcium deposits
in the vasculature; in turn, this observation is consistent
with the inverse association between circulating t-ucMGP
levels and the VC score.
A few studies have evaluated the association between
MGP levels and VC in patients with diabetes [11-13], al-
though the researchers used different antibodies to de-
termine either circulating dp-ucMGP [11], t- ucMGP
[12] or other conformations of ucMGP [12,14]. There
are few data on (i) the levels of different MGP forms in
a selected population with type 2 diabetes and (ii) therelationships between these various forms and peripheral
artery calcification. This knowledge would be useful,
since as Dalmeijer et al. have recently demonstrated that
high dp-ucMGP levels were associated with increased
cardiovascular risk (PAD and heart failure) in patients
with type 2 diabetes [11]. Furthermore, Doyon et al. used
a rat model of diabetes to show that the decrease in ac-
tive carboxylated MGP (cMGP) levels could be due to an
impairment of gammaglutamate carboxylation - suggest-
ing that the signalling pathways involved in gammagluta-
mate carboxylase regulation are altered in diabetes [15].
The objective of the present study of patients with
type 2 diabetes and normal or slightly altered kidney
function was to evaluate (i) t-ucMGP and dp-ucMGP
levels, (ii) biochemical and clinical parameters associated
with differences in dp-ucMGP and t-ucMGP levels and




The study was performed in accordance with the princi-
ples of the Declaration of Helsinki and in compliance
with the International Conference on Harmonization's
guidelines on good clinical practice. The study protocol
was approved by the local independent ethics committee
(Comité de Protection des Personnes, Paris, France) prior
to the initiation of any study-specific procedures. All pa-
tients were provided with full information on the study
objectives and procedures and gave their written in-
formed consent to participation.
Patient selection
In the "Diabète et Calcification Arterielle" (DIACART)
cross-sectional study, 198 patients with type 2 diabetes
from the Diabetology Department and the Cardiology
Department at Pitié-Salpêtrière Hospital (Paris, France)
were included over an 8-month period. The objective of
DIACART study was to gain a better understanding of
the pathophysiology of peripheral artery calcification in
diabetic patients. The main inclusion criteria were (i)
type 2 diabetes, with at least coronary artery disease
and/or peripheral arterial occlusive disease and (ii) age >50
for men and >60 for women. The main exclusion criteria
were (i) an estimated glomerular filtration rate (eGFR, cal-
culated with the Modification of Diet in Renal Disease
equation) <30 ml/min and (ii) a history of lower limb
angioplasty and/or bypass.
Study protocol
All patients were hospitalized for the day in order to per-
form clinical evaluations, laboratory blood tests and a
multislice spiral computed tomography (CT) scan. A pa-
tient interview focused on comorbidities and the personal
Table 1 Univariate logistic regression analysis: variables
associated with calcification score divided by the median
(n = 198 patients)
Odds ratio (95% confidence interval) p
Age 1.07 (1.03; 1.11) <0.0001
Ln [t-ucMGP] 0.27 (0.11; 0.63) 0.003
Ln [dp-ucMGP] 1.88 (1.21; 2.91) 0.005
Gender 2.56 (1.36; 4.75) 0.006
Previous CVD 2.56 (1.36; 4.75) 0.004
For abbreviations, please refer to Table 3.
Variables not significantly associated: diabetes duration, smoking status,
VKA treatment, body mass index, SBP, DBP, GFR-MDRD, glycaemia, HbA1c,
microalbuminuria, IL6, cholesterol, C-reactive protein, 25(OH) Vit D,
calcium, phosphate.
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reviewed to check the information and to record vitamin
K antagonist (VKA) use.
Previous CVD was defined as a history of any of the
following events: myocardial infarction, stroke or any
surgical procedures for angina or coronary disease (in-
cluding percutaneous transluminal angioplasty).
Laboratory tests
Blood and urine samples were collected after an overnight
fast for measurement of routine biochemistry, glycaemia,
HbA1C, high-sensitivity C-reactive protein, calcium, phos-
phorus, 25-OH vitamin D, intact parathyroid hormone
(PTH), triglycerides and cholesterol.
Selected assays (including dp-ucMGP and t-ucMGP as-
says) were performed after the samples had been frozen,
stored at −80°C and thawed. A dual-antibody ELISA was
used to measure dp-ucMGP levels; the capture antibody
was directed against the non-phosphorylated MGP se-
quence 3–15 (mAb-dpMGP; VitaK BV, Maastricht, The
Netherlands) and the detecting antibody was directed
against the uncarboxylated MGP sequence 35–49 (mAb-
ucMGP; VitaK BV). The same antibodies have already been
used for immunohistochemical staining [16-18]. Intra-assay
variability was 5,6% for dp-ucMGP and 8,9% for t-ucMGP,
when inter-assay variability was 9,9% for dp-ucMGP and
11,4% for t-ucMGP. In 81 age-matched controls, the mean
level of dp-ucMGP was 557 ± 277 pM (median: 522 pM)
(measured separately in archived samples).
A competitive (single-antibody) ELISA was used to
measure t-ucMGP levels, as described previously [9,19].
In 81 age-matched controls, the mean t-ucMGP level
was 4282 ± 1100 nM (median: 4109 nM).
Imaging for calculation of the below-knee arterial
calcification score
Tibial artery calcium scoring was performed after scanning
with a 128-slice multidetector CT scanner (Somatom Defin-
ition Flash, Siemens Healthcare, Forchheim, Germany) in the
craniocaudal direction, from the bottom of the patella down
to the ankle region. Contrast agent was not used. Cross-
sectional slices (with: 3 mm) were analyzed individually.
The analysis was performed with a commercially available
software package (Heartbeat CaScore, Philips Healthcare,
Eindhoven, The Netherlands) by radiologists who were not
aware of the results of the clinical examination or laboratory
assays, On cross-sectional images, areas of calcification along
below-knee arteries with a density ≥130 Hounsfield units
and a surface >1 mm2 were identified automatically. The
calcification scores (determined according to the method
described by Agatston et al. [20]) for each of the main
below-knee arteries (the distal popliteal, anterior tibial, pos-
terior tibial and peroneal arteries) were summed to obtain
the overall calcification score.Statistical analyses
Data were expressed as the mean ± SD, median or fre-
quency, as appropriate. The study patients were strati-
fied according to the median dp-ucMGP level. This
median value appears to be the best available cut off, ac-
cording to the receiver operating characteristic curve for
VC (with a sensitivity of 0.65 and a specificity of 0.70).
Intergroup comparisons were made using a χ2 test for
categorical variables and Student’s t test or the Kruskall-
Wallis test for continuous variables. Spearman correla-
tions were used to identify parameters correlated with
dp-ucMGP levels and t-ucMGP. For parameters present-
ing a non-Gaussian distribution, log-normalized values
were considered in tests that require normally distributed
variables. Multiple linear regression analysis was used to
select factors that were independently associated with dp-
ucMGP levels. Unadjusted (Table 1) and adjusted (Table 2)
logistic regression analyses were performed to evaluate the
association between the peripheral calcification score (as
categorized by the median) and dp-ucMGP. A p value ≤
0.05 was considered to be statistically significant. All stat-
istical analyses were performed using SPSS software (ver-
sion 13.0, SPSS Inc., Chicago IL, USA) for Windows
(Microsoft Corp., Redmond WA, USA).
Results
Baseline characteristics
Table 3 presents the main clinical and biochemical char-
acteristics for the entire cohort and for the subgroups
above and below the median dp-ucMGP (559.5 pM)
value. Patients with higher plasma dp-ucMGP levels
were significantly older, were more likely to taking VKAs
and had higher body mass index, PTH levels and trigly-
ceride levels and a lower eGFR. Patients with higher
plasma t-ucMGP levels (i.e. above to the median t-
ucMGP value (4741 nM) were significantly younger, had
higher body mass index, diastolic blood pressure, cal-
cium and triglyceride levels and lower PTH levels. It is
noteworthy that although only six patients were being
Table 2 Multivariate logistic regression analysis: variables
independently associated with the calcification score
divided by the median (n = 198 patients)
Odds ratio (95% confidence interval) p
Age per 1 year 1.06 (1.02; 1.11) 0.006
Ln [t-ucMGP] 0.44 (0.17; 1.15) 0.092
Ln [dp-ucMGP] 1.88 (1.14; 3.11) 0.014
Male gender 3.84 (1.66; 8.88) 0.002
Previous CVD 2.56 (1.20; 4.85) 0.013
Variables entered into the model: age, Ln [dp-ucMGP], Ln [t-ucMGP], gender,
previous CVD.
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higher than in untreated patients (the mean and median
dp-ucMGP levels were 2093 ± 1125 pM and 1984 pM for
VKA-treated patients and 581 ± 327 pM and 553 pM for
non-VKA-treated patients). Treatment with renin angio-
tensin aldosterone inhibitors was not associated with
changes in levels of MGP forms or in the calcification
score. We also compared patients as a function of their
HbA1c levels (above vs. below 7%) but found no difference
in terms of either VC, t-ucMGP or dp-ucMGP.MGP values as a function of the calcification score
Patients with an above-median peripheral arterial score
had significantly lower t-ucMGP levels (median: 4941 nM
vs. 4550 nM, respectively; p = 0.006) and significantly
higher dp-ucMGP levels (median: 480 pM vs. 652 pM re-
spectively; p = 0.001).Associations between dp-ucMGP and calcification
A univariate correlation analysis with plasma dp-ucMGP
essentially confirmed the results as described in Table 3
(Table 4). These findings did not change when the six
VKA-treated patients were excluded from the analyses.
Moreover, a multivariate linear regression analysis (in-
cluding all variables significantly associated with plasma
dp-ucMGP levels in the univariate analyses) identified
eGFR (p < 0.0001), age (p =0.002) and current antivita-
min K use (p < 0.0001) as independent factors.
In the present cohort, we found that age, male gender,
previous CVD, and dp-ucMGP levels were positive risk
factors for an elevated calcification score, whereas t-
ucMGP appeared to protect against VC in a univariate
analysis (Table 1). Furthermore, in a multivariate logistic
analysis, dp-ucMGP appeared to an independent pre-
dictor of peripheral arterial calcification (independently
of age, gender, previous CVD and t-ucMGP levels)
(Table 2). Patients with high dp-ucMGP presented an el-
evated risk of VC, independently of classical risk factors.
Similar evidence was obtained after the exclusion of
VKA-treated patients from the analysis.Discussion
The present study is the first to show that in patients
with type 2 diabetes and normal or slightly altered kid-
ney function, dp-ucMGP levels (a marker for vitamin K
status) are independently associated with age, eGFR and
VKA treatment. More importantly, peripheral VC is as-
sociated with dp-ucMGP (independently of age, gender,
previous CVD and t-ucMGP levels).
Matrix Gla protein is a strong inhibitor of VC, as re-
vealed by the development of massive VC in MGP knock-
out mice [21]. Indeed, MGP is a vitamin K-dependent
inhibitor of calcium phosphate precipitation and crystal
formation in the vessel wall [22]. Furthermore, it sup-
presses the activity of bone morphogenetic proteins 2 and
4 [22,23]. The value of MGP as a calcification biomarker
has been evaluated in various cohorts, and a number of
assays have been developed to measure its various confor-
mations. In the present study, we evaluated circulating t-
ucMGP and dp-ucMGP concentrations. We focused on
dp-ucMGP because this form has low affinity for vascular
calcium deposits and is secreted into the bloodstream by
vascular smooth muscle cells. Moreover, dp-ucMGP is a
well-known marker for vascular vitamin K status. High
levels of dp-ucMGP have been associated with aortic calci-
fication (independently of classical risk factors) in patients
at different stages of CKD [10,24]. Similarly, the present
study is the first to demonstrate that in patients with type
2 diabetes and normal or slightly altered kidney function,
dp-ucMGP levels were positively associated with periph-
eral artery calcification (independently of age, gender, pre-
vious CVD and t-ucMGP). It is important to study VC
in diabetic patients, since as calcification process could
present specific features. Indeed Flammer et al. recently
reported that patients with elevated HbA1c levels had a
significantly higher percentage of circulating blood mono-
nuclear cells expressing the osteoblastic marker osteocal-
cin. However, further research is required to establish
whether these cells increase VC [25]. On the same lines, a
distinct subpopulation of circulating cells expressing
osteocalcin and bone alkaline phosphatase had procalcific
activity in type 2 diabetic patients [26].
Indeed, the present study is the first to have evaluated
the potential role of this important calcification inhibitor
and its relationship with peripheral artery calcification (as
evaluated with a CT-based methodology). This result is in
agreement with recently published data from a prospective
study of 518 patients with type 2 diabetes (mean follow-up
period: 11.2 years); Dalmeijer et al. demonstrated a strong,
independent relationship between high dp-ucMGP and
cardiovascular risk (and PAD in particular), whereas t-
ucMGP levels were not associated with CVD [11]. Indeed,
the presence of medial calcification (which is particularly
present in peripheral arteries [27]) could explain the posi-
tive correlation between dp-ucMGP levels and PAD.
Table 3 Baseline characteristics as a function of the median plasma dp-ucMGP level
All [dp-ucMGP] ≤ 559.5 pM [dp-ucMGP] > 559.5 pM p
n = 198 n = 99 n = 99
Age (years) 64 ± 8 63 ± 9 66 ± 8 0.002
Diabetes duration (years) 15 ± 10 14 ± 10 15 ± 9 0.358
Male gender n (%) 158 (80) 82 (83) 76 (77) 0.288
Body mass index (kg/m2) 29 ± 5 28 ± 5 30 ± 5 <0.0001
SBP (mmHg) 127 ± 17 126 ± 17 128 ± 17 0.377
DBP (mmHg) 73 ± 9 73 ± 9 72 ± 8 0.487
Smoking habit n (%) 119 (60) 58 (59) 61 (62) 0.663
Previous CVD n (%) 139 (70) 66 (67) 73 (74) 0.277
Glycaemia (mmol/l) 8.2 ± 2.8 8.0 ± 2.6 8.3 ± 2.9 0.401
(7.8) (7.6) (8.0)
HbA1c (%) 7.8 ± 1.5 (7.5) 7.7 ± 1.4 7.9 ± 1.5 0.572
(7.5) (7.5)
GFR MDRD (mmol/l) 80 ± 19 82 ± 19 70 ± 19 <0.0001
Microalbuminuria (mg/l) 166 ± 840 169 ± 1132 162 ± 373 <0.0001
(23) (14) (33)
Calcium (mmol/l) 2.30 ± 0.10 2.30 ± 0.10 2.34 ± 0.10 0.055
Phosphate (mmol/l) 1.02 ± 0.15 1.04 ± 0.20 1.00 ± 0.20 0.164
Intact PTH 54.5 ± 27.5 50.8 ± 26.0 58.5 ± 28.9 0.030
(pg/mL) (46.9) (45.2) (52.0)
25(OH)Vit D (ng/ml) 13.8 ± 8.4 14.4 ± 8.2 13.2 ± 8.5 0.175
(12.0) (13.0) (11.0)
CRP 2.2 ± 1.5 2.2 ± 2.6 2.2 ± 2.5 0.725
(mg/l) (1.2) (1.3) (1.1)
Triglycerides 1.6 ± 1.1 1.4 ± 1.1 1.6 ± 0.9 0.039
(mmol/L) (1.3) (1.2) (1.4)
Total cholesterol (mmol/l) 3.7 ± 0.9 3.7 ± 0.8 3.8 ± 0.9 0.283
LDL cholesterol 1.9 ± 0.7 1.9 ± 0.7 2.0 ± 0.8 0.403
(mmol/L) (1.8) (1.8) (1.8)
Total cholesterol/HDL 3.7 ± 1.6 3.5 ± 1.1 3.9 ± 1.8 0.053
cholesterol (3.5) (3.3) (3.5)
Peripheral calcification score 2528 ± 5779 1609 ± 3983 3447 ± 7040 <0.0001
(524) (274) (1096)
t-ucMGP (nM) 4868 ± 1613 4815 ± 1689 4921 ± 1539 (4787) 0.460
(4741) (4616)
dp-ucMGP (pM) 627 ± 451 342 ± 142 912 ± 474 NA
(559) (352) (755)
VKA treatment n (%) 6 (3) 0 (0) 6 (6) 0.013
Data are given as means ± SD for normally distributed measures with addition of (median) for non-normally distributed values for variables with a non-Gaussian
distribution or as the number (percentage) for binary variables.
SBP: systolic blood pressure; DBP: diastolic blood pressure; CVD: cardiovascular disease; HbA1c: haemoglobin A1C; GFR MDRD: Glomerular filtration rate calculated
with the Modification of Diet in Renal Disease formula; PTH: parathyroid hormone; CRP: C-reactive protein, t-ucMGP: total uncarboxylated matrix Gla-protein;
dp-ucMGP: dephospho-uncarboxylated matrix Gla-protein. VKA: vitamin K antagonist.
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ported that higher t-ucMGP levels are associated with
lower mitral annular calcification (MAC) in persons
without diabetes and higher MAC in persons withdiabetes [12]. In the present study, a univariate analysis
revealed an inverse relationship between t-ucMGP and
peripheral artery calcification; however, this link was no
longer significant after adjustment for dp-ucMGP. The
Table 4 Univariate correlations: variables associated with plasma dp-ucMGP levels and t-ucMGP levels
dp-ucMGP levels t-ucMGP levels
r p r p
Age 0.294 <0.0001 −0.306 <0.001
Diabetes duration 0.077 0.278 −0.133 0.062
Body mass index 0.250 <0.0001 0.291 <0.0001
SBP 0.027 0.710 0.171 0.016
DBP −0.105 0.142 0.324 <0.0001
Glycaemia 0.046 0.520 0.130 0.069
HbA1c 0.034 0.638 0.105 0.141
GFR MDRD −0.410 <0.0001 0.211 0.003
Microalbuminuria 0.307 <0.0001 −0.021 0.766
Calcium 0.145 0.042 0.255 <0.0001
Phosphate −0.089 0.214 −0.095 0.182
Intact PTH (pg/mL) 0.197 0.005 −0.256 <0.0001
25(OH)D −0.095 0.181 −0.009 0.903
C-reactive protein 0.137 0.055 0.110 0.120
Triglycerides 0.215 0.002 0.312 <0.0001
Total cholesterol 0.084 0.240 0.079 0.268
Total cholesterol/HDL cholesterol 0.188 0.008 0.202 0.004
t-ucMGP 0.052 0.467 1.000 <0.0001
Peripheral calcification score 0.260 <0.0001 −0.272 <0.0001
For abbreviations, please refer to Table 3. r = Spearman correlation coefficient.
Liabeuf et al. Cardiovascular Diabetology 2014, 13:85 Page 6 of 8
http://www.cardiab.com/content/13/1/85conflicting results in these two studies might be due to
differences in the calcification site evaluated (MAC ver-
sus peripheral calcification) and patient recruitment
(outpatients with stable CVD versus patients in a dia-
betes ward). However, it appears to be important to
assay for dp-ucMGP when focusing on peripheral VC,
since this factor is still associated with peripheral artery
calcification after multiple adjustments. Furthermore,
Dalmeijer et al. reported that dp-ucMGP levels (but not
t-ucMGP levels) were associated with PAD. These find-
ings suggest that VC sites differ in terms of their specific
features and biomarkers. This is of particular interest in
the pathophysiology of VC in patients with diabetes,
who are particularly prone to this condition. Indeed, per-
ipheral artery calcification is very frequent in patients
with diabetes and can lead to amputation.
Furthermore, we identified eGFR, age and current VKA
use as independent factors for dp-ucMGP levels. It is
already know that in patients with CKD, levels of inactive
forms of MGP increase progressively [10]. Even when pa-
tients with normal or slightly altered kidney function are
selected, eGFR is still a strong predictor of MGP levels. It
is noteworthy that the link between dp-ucMGP levels and
calcification appeared to be independent of kidney func-
tion in the present study.
The use of VKAs appears to be an important predictor
of dp-ucMGP; the six VKA-treated patients had dp-ucMGP levels that were around 4 times greater than in
the other patients. Indeed, VKA treatment indirectly in-
hibits the carboxylation of vitamin K-dependent proteins
via interactions with vitamin K epoxide reductase. Hence,
VKA treatment inhibits the gamma-carboxylation of MGP
and leads to an increase in inactive forms of MGP and
thus prompts VC [28,29]. Indeed, epidemiological studies
performed in the last decade have revealed VC in warfarin-
treated patients [29].
Until recently, VKAs were the only drugs for long-
term treatment of thromboembolic disorders. However,
novel new oral anticoagulant agents (NOACs) have now
emerged (e.g. factor Xa inhibitors such as rivaroxaban,
apixaban and factor IIa inhibitors such as dabigatran).
Unlike VKAs, the NOACs do not interfere with vitamin
K-dependent proteins and may thus be safer with regard
to VC. This advantage is particular important in diabetic
populations, who are particular prone to the develop-
ment of VC. However, this hypothesis needs to be con-
firmed in prospective trials and balanced against the
efficacy and safety of NOACs.
Given that VC in general and peripheral calcification in
particular are major problems in patients with diabetes,
modulation of vitamin K status might be an interesting
therapeutic option. Indeed, vitamin K is gaining increasing
attention in terms of its therapeutic potential in VC
[30,31]. In a recent pilot study, vitamin K supplementation
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vitamin K status. Indeed, short-term supplementation with
menaquinone-7 (vitamin K2) was found to reduce dp-
ucMGP levels in haemodialysis patients [32]. It remains to
be seen whether vitamin K supplementation could have
an impact on VC in patients with diabetes (through evalu-
ation in large clinical trials).
The limitation of the present study included the small
sample size, the lack of evaluation of vitamin K intake and
serum vitamin K levels, and the evaluation of marker
levels at a single time point. The study would have been
strengthened by the presence of a control group of partici-
pants with vascular calcification data, so that they could
have been compared with diabetic patients. In contrast,
one of the study’s main strengths relates to the fact that
this was the first study to concomitant evaluate dp-
ucMGP/t-ucMGP and peripheral artery calcification in pa-
tients with type 2 diabetes.
Conclusion
In patients with type 2 diabetes, with high cardiovascular
risk and normal or slightly altered kidney function, ele-
vated dp-ucMGP levels are independently correlated
with the severity of peripheral artery calcification.
Hence, dp-ucMGP may be a valuable biomarker in pa-
tients with diabetes. The reversibility of the elevation of
dp-ucMGP levels and the latter’s relationship with clin-
ical events merit further investigation.
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